Product Pipeline

Targeting High-Priority Drugs and Innovative Devices to Address Unmet Medical Needs

Reliis has several high priority drugs and one device for which there is deemed a significant unmet need and viable market.

Serveral additional drugs have been identified by our specialist clinicians are under review by the Scientific Advisory Board.

RLS-Q2201

Successful treatment and management of agitated delirium, a condition that presents as a state of mental confusion, restlessness, and agitation often occurs in medical settings, particularly in critically ill or hospitalised patients is limited. Despite its prevalence and severity, there is currently no registered treatment specifically formulated to address this condition.

Current pharmacological interventions for agitated delirium typically involve the use of sedatives and antipsychotic medications. These interventions aim to manage the symptoms of agitation, hallucinations, and delusions commonly associated with the condition. However, as there is no specific medication approved for the treatment of agitated delirium, clinicians are forced to utilise off-label use of medications such as benzodiazepines, antipsychotics, and sedatives. These pharmacological interventions are associated with various limitations, including variable efficacy, risk of adverse effects, death, and challenges in dosing and administration.

Recognising the pressing need for innovative new, safe, and effective treatments for agitated delirium, Reliis has developed a novel reformulation presented in an injectable format, known as RLS-Q2201. This formulation is designed to be administered both intravenously (IV) and subcutaneously (SC), providing versatility in treatment administration.

RLS-M2202

Following major surgery, patients often experience hypotension requiring ICU admission, but many cannot take oral tablets due to their surgical condition. Reliis addresses this challenge with its innovative product, RLS-M2202. Whilst the current treatment is effective in controlling blood pressure, its utility is limited for patients unable to swallow tablets post-surgery.

Reliis has successfully reformulated the current tablet treatment into a sublingual oral spray, allowing administration to patients unable to swallow tablets. This advancement not only benefits patients clinically by potentially avoiding ICU admissions and reducing long-term health implications but also offers potential cost savings for healthcare systems.

The reformulation addresses a significant unmet clinical need, particularly in patients undergoing major abdominal surgery, where post-operative hypotension occurs in up to 42% of cases. With a provisional patent in place, Reliis plans to register RLS-M2202 globally, focusing on key markets like the US, Australia, and Europe. By targeting major abdominal surgery patients without contraindications, RLS-M2202 aims to improve patient outcomes while offering a valuable solution to healthcare providers worldwide.

RLS-C2203

Introducing RLS-C2203, Reliis’ ultra-pure Medicinal CBD formulation. Our advanced oral liquid cannabinoid product offers unparalleled purity, stability, and manufacturing reproducibility, setting a new standard in CBD therapeutics. With no THC, odour, or taste, RLS-C2203 enhances patient tolerability and compliance, simplifying prescription and administration.

TGA-approved via the Special Access Scheme (SAS) and Authorised Prescribers (AP) pathways, RLS-C2203 has completed Phase II clinical trials in cancer patients, demonstrating safety and excellent tolerability. As one of the few CBD products to undergo rigorous clinical testing, it opens doors to multiple clinical indications with vast market potential.

In a rapidly growing global market estimated at AUD$80 billion, RLS-C2203 stands at the forefront of medicinal cannabis innovation. In Australia alone, where legal prescriptions have been available since 2016, the market continues to expand, with significant increases in prescribers and approvals.

With CBD’s wide-ranging therapeutic potential, from pain management to improved sleep and mood, RLS-C2203 represents a transformative option for patients seeking natural remedies supported by clinical evidence. Join us in unlocking the full potential of CBD with Reliis’ Ultrapure Medicinal CBD (RLS-C2203).

RLS-D2204

The Intranasal Actuator Device developed by Reliis is set to be a groundbreaking medical device designed to address the unmet clinical need for fast and accurate drug delivery, particularly in patient groups where intravenous (IV) access is challenging or not feasible, such as children, cognitively impaired individuals, and agitated or anxious patients.

In various settings including Emergency Departments (EDs), prehospital environments like ambulances and remote sites, as well as military settings, IV access can be difficult or impossible. This poses significant challenges for administering opioid analgesics and sedative drugs effectively.

Reliis’ solution is an intranasal actuator system that facilitates rapid and precise drug delivery via the nasal route, enabling quick control of pain and agitation. This, in turn, allows for subsequent IV access when necessary. The device offers several advantages, including improved safety by reducing staff exposure to needles and the risk of needle stick injuries.

Furthermore, the device features tamper-proof and tamper-evident packaging to prevent drug diversion or misuse, ensuring the integrity of medication administration. With its versatility and potential to enhance patient care in a wide range of settings and patient groups, the Intranasal Actuator Device represents an important advancement in medical technology.

The Intranasal Actuator Device developed by Reliis is currently in Stage 1: Proof of Concept. Reliis is actively engaged with industrial designers for the development of prototypes, marking a significant step towards realising the concept into a tangible medical device.